402 related articles for article (PubMed ID: 20357284)
1. Clinical practice. Prolactinomas.
Klibanski A
N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
[No Abstract] [Full Text] [Related]
2. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
3. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
[TBL] [Abstract][Full Text] [Related]
4. Medical management of prolactin-secreting pituitary adenomas.
Molitch ME
Pituitary; 2002; 5(2):55-65. PubMed ID: 12675502
[TBL] [Abstract][Full Text] [Related]
5. [Macroprolactinoma].
von Werder K
Dtsch Med Wochenschr; 1996 Jul; 121(30):962. PubMed ID: 8777896
[No Abstract] [Full Text] [Related]
6. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
7. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
9. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Araujo B; Belo S; Carvalho D
Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
[No Abstract] [Full Text] [Related]
10. Prolactinoma.
Serri O; Beauregard H; Somma M
Curr Ther Endocrinol Metab; 1994; 5():41-3. PubMed ID: 7704764
[No Abstract] [Full Text] [Related]
11. Clinical practice. Prolactinoma.
Schlechte JA
N Engl J Med; 2003 Nov; 349(21):2035-41. PubMed ID: 14627789
[No Abstract] [Full Text] [Related]
12. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
13. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
14. [Risk of prolactinoma growth during pregnancy. Visual field tests required in macroadenoma, small risk in microadenomas].
Ericsson C; Lindblom B
Lakartidningen; 2012 Jun 19-26; 109(25):1226-8. PubMed ID: 22838112
[No Abstract] [Full Text] [Related]
15. Diagnosis and treatment of prolactinomas.
Molitch ME
Adv Intern Med; 1999; 44():117-53. PubMed ID: 9929707
[No Abstract] [Full Text] [Related]
16. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
17. Ten-year follow-up of a giant prolactinoma.
Fernandes V; Santos MJ; Almeida R; Marques O
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26590188
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
20. Giant macroprolactinoma and pregnancy.
Saraiva J; Gomes L; Paiva S; Ruas L; Carvalheiro M
Arq Bras Endocrinol Metabol; 2013 Oct; 57(7):558-61. PubMed ID: 24232822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
